Results 101 to 110 of about 39,846 (264)

Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling

BMC Veterinary Research, 2019
Background Mammary gland tumor is the most common spontaneous tumor in intact female dogs, and its poor prognosis remains a clinical challenge. Ivermectin, a well-known anti-parasitic agent, has been implicated as a potential anticancer agent in various ...
Hongxiu Diao, Nan Cheng, Ying Zhao, Huihao Xu, Haodi Dong, Douglas H. Thamm, Di Zhang, Degui Lin   +7 more
doaj   +1 more source

Mare colostrum quality and relationship with foal serum immunoglobulin G concentrations and average daily weight gains

Equine Veterinary Journal, Volume 57, Issue 4, Page 904-914, July 2025.
Abstract Background Foals suffer from total failure to transfer passive immunity (TFTPI) when serum immunoglobulin (IgG) is <4 g/L, and partial failure to transfer passive immunity (PFTPI) when serum IgG is 4–8 g/L. Objectives To explore risk factors for poor serum IgG concentration. Study design Retrospective observational study. Methods Data from 535
Kirsty Gallacher, Katherine Champion, Katharine S. Denholm   +2 more
wiley   +1 more source

ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19

medRxiv, 2020
Importance: No therapy to date has been shown to improve survival for patients infected with SARS-CoV-2. Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in vitro but clinical response has not been previously evaluated.
J. C. Rajter, Michael Sherman, N. Fatteh, Fabio Vogel, Jamie Sacks, J. Rajter   +5 more
semanticscholar   +1 more source

Ivermectin inhibits the growth of ESCC by activating the ATF4-mediated endoplasmic reticulum stress-autophagy pathway

Acta Biochimica et Biophysica Sinica
Esophageal squamous cell carcinoma (ESCC) is one of the most common forms of malignancy worldwide. However, there is currently a lack of effective chemotherapeutic drugs for ESCC.
Liu Huiyang, Chai Zhirong, Gao Ya, Wang Yanming, Lu Mengmeng   +4 more
doaj   +1 more source

Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19

Annals of Clinical Microbiology and Antimicrobials, 2020
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the ...
K. Sharun, K. Dhama, S. K. Patel, M. Pathak, R. Tiwari, B. Singh, R. Sah, D. Bonilla-Aldana, A. Rodríguez-Morales, H. Leblebicioglu   +9 more
semanticscholar   +1 more source

Ivermectin: Difficulties in resolving pharmacokinetic and pharmacodynamic relationships in onchocerciasis

International Journal of Medicine and Health Development, 2004
Aim: To elucidate the non-drug related factors involved in the unique actions of ivermectin and the disassociation between plasma ivermectin concentrations, the commencement of microfilaricidal effects and adverse events.
E N Shu, 0 E Onwujekwe, P 0 Okonkwo
doaj  

Ivermectin treatment of onchocerciasis [PDF]

Australian and New Zealand Journal of Ophthalmology, 1989
AbstractIvermectin is a recently developed macrocyclic lactone that has. widespread antiparasitic activity. A series of clinical trials has shown that ivermectin is safe and effective in the treatment of human infection with Onchocerca volvulus.
openaire   +3 more sources

Knowledge, attitude and prevalence of ivermectin use as coronavirus disease treatment: A cross-sectional study among a Malaysian population [PDF]

Malaysian Family Physician
Introduction: During the coronavirus disease (COVID-19) pandemic, there was a widespread public misconception regarding ivermectin use in managing the disease.
Filza Nur Athirah Tar’ali, Aina Amanina Abdul Jalil, Nor Safwan Hadi Nor Afendi   +2 more
doaj   +1 more source

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Antiviral Research, 2020
L. Caly, J. Druce, M. Catton, D. Jans, K. Wagstaff   +4 more
semanticscholar   +1 more source

Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. Reply.

New England Journal of Medicine, 2022
C. Bramante, J. Huling, C. Tignanelli, J. Buse, David M. Liebovitz, J. Nicklas, K. Cohen, M. Puskarich, H. Belani, J. Proper, L. Siegel, N. Klatt, D. Odde, Darlette G. Luke, Blake Anderson, A. Karger, N. Ingraham, K. Hartman, V. Rao, Aubrey A Hagen, Barkha P Patel, S. Fenno, N. Avula, N. V. Reddy, S. M. Erickson, S. Lindberg, R. Fricton, Samuel Lee, A. Zaman, Hanna G Saveraid, Walker J Tordsen, M. Pullen, M. Biros, N. Sherwood, Jennifer L. Thompson, D. Boulware, T. Murray   +36 more
semanticscholar   +1 more source